"In 2011, the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) 4 introduced a classification and terminology for adenocarcinoma of the lung. The term bronchoalveolar carcinoma (BAC) has fallen out of favour and "invasive mucinous adenocarcinoma of the lung" is the term used for the tumours previously known as "mucinous bronchoalveolar carcinoma (BAC)"."
"Although also consisting of a mixture of histologic patterns, e.g. lepidic, acinar, papillary, micropapillary, and solid growth, as we observe in the non-mucinous invasive tumours, there is no recommendation to subcategorise the invasive mucinous adenocarcinomas, as the clinical relevance of doing so is still uncertain 4."
"KRAS mutation: strongly present (~76%) 4,5"
"EGFR mutation: almost always absent (~3%) 4,5"
"In 2011, the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) 4 introduced a classification and terminology for adenocarcinoma of the lung. The term bronchoalveolar carcinoma (BAC) has fallen out of favour and "invasive mucinous adenocarcinoma of the lung" is the term used for the tumours previously known as "mucinous bronchoalveolar carcinoma (BAC)"."
"Although also consisting of a mixture of histologic patterns, e.g. lepidic, acinar, papillary, micropapillary, and solid growth, as we observe in the non-mucinous invasive tumours, there is no recommendation to subcategorise the invasive mucinous adenocarcinomas, as the clinical relevance of doing so is still uncertain 4."